CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), the company behind the first FDA- and European Commission–approved drug for MASH, will spotlight its flagship therapy in a pair of fireside chats at major investor conferences next week.
The biopharmaceutical firm is scheduled to present at the 8th Annual Evercore Healthcare Conference on Tuesday, Dec. 2, 2025, at 4:15 p.m. ET, followed by an appearance at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, Dec. 3, 2025, at 1:30 p.m. ET. Both discussions will be webcast live through the company’s Investor Relations Events page.
Madrigal has drawn widespread investor interest following the approval of its once-daily oral therapy, Rezdiffra (resmetirom). The medication, a liver-directed THR-β agonist, treats metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis — a disease area long marked by failed drug candidates and significant unmet medical need.
The company is also pursuing expanded indications. A Phase 3 outcomes trial is underway evaluating Rezdiffra for compensated MASH cirrhosis, a more advanced stage of the disease that affects millions worldwide but currently lacks effective pharmacological treatment options.
Madrigal’s conference appearances come at a pivotal time for both the company and the rapidly evolving MASH therapeutics market, where demand for scalable, effective treatments continues to surge.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.